Nathan A. Beaton

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA

Nathan Beaton, an associate in the Washington, D.C. office of Latham & Watkins and a member of the Healthcare & Life Sciences Practice, focuses his practice on regulatory, transactional, and legislative matters involving industries overseen by the Food and Drug Administration (FDA) and other federal health authorities.

Mr. Beaton represents pharmaceutical, biotechnology, medical device, digital health, and consumer product companies on FDA regulatory compliance and enforcement matters. He counsels at all stages of the product life cycle, including, among others, pre-market regulatory communications and submissions, contract matters relating to clinical trials, non-patent exclusivity, post-market actions and recalls, and administrative interactions and appeals.

He also advises on matters involving the Drug Enforcement Administration (DEA), US Department of Agriculture (USDA), and Federal Trade Commission (FTC). 

Mr. Beaton provides counsel concerning legislation and administrative rulemaking, including matters involving the implementation of the Agriculture Improvement Act of 2018, FDA Reauthorization Act of 2017, and Family Smoking Prevention and Tobacco Control Act of 2009. He has been involved extensively in Administrative Procedure Act litigation related to FDA actions and regulatory programs.

Mr. Beaton advises investment banks, venture capital firms, private equity firms, and commercial lenders on regulatory matters in connection with mergers and acquisitions, equity offerings, financings, and other transactions in the life sciences sector.

Mr. Beaton earned his Juris Doctor from University of Chicago Law School, with honors, and a Master of Public Policy from the University of Chicago Harris School, where he studied health economics and policy.

He currently serves as a member of the Food and Drug Law Institute’s H. Thomas Austern Writing Awards Committee.

Thought Leadership

Mr. Beaton’s recent publications and speaking engagements include: 

  • “Introduction to Drug Law and Regulation,” Food and Drug Law Institute (November 2019)
  • “FDA Announces Planned Changes to the 510(k) Premarket Notification Program,” Latham & Watkins Client Alert (December 2018) 
  • “Examining the FDA Reauthorization Act Add-On Provisions,” Law360 (August 2017)
  • “FDA Reauthorization Act Aims to Speed Product Reviews Through User Fee Funding,” Latham & Watkins Client Alert (August 2017)
  • “ACA 'Repeal and Replace' Bill Merits Attention from Industry Stakeholders," Latham & Watkins Client Alert (May 2017)
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.